Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on addressing drug resistance in cancer, announced that President and Chief Scientific Officer Neil Bhowmick is presenting interim efficacy results for its lead candidate ENV-105 at the 11th International Conference on Cancer Research & Drug Development in Houston on Nov. 3, 2026. The presentation highlights the potential of ENV-105, a first-in-class CD105/BMP signaling inhibitor, in overcoming treatment resistance for patients with EGFR-driven non-small cell lung cancer and metastatic castration-resistant prostate cancer (mCRPC).
According to the announcement, an interim analysis of the Phase 2 trial demonstrated a statistically significant improvement in median progression-free survival (PFS) among patients receiving ENV-105 plus apalutamide compared with apalutamide alone. Median PFS was 17.7 months versus two months, respectively (P=0.0008). The trial will now focus on first-line therapy after enzalutamide, incorporating first-line resistance in a larger patient group. This shift underscores the company's strategy to address resistance mechanisms that emerge after standard treatments.
The implications for patients and the oncology field are substantial. Prostate cancer remains a leading cause of cancer death among men, and resistance to therapies like apalutamide and enzalutamide often leads to rapid disease progression. If ENV-105 can extend PFS by nearly 16 months compared to apalutamide alone, it could represent a meaningful clinical benefit. Bhowmick said the findings support the company's hypothesis that targeting CD105 may interrupt mechanisms of treatment resistance and restore sensitivity to established cancer therapies. Previous preclinical research has also demonstrated the potential of ENV-105 to enhance radiation sensitivity in prostate cancer models, suggesting broader applications.
For investors and industry observers, the interim data provide early validation of Kairos Pharma's structural biology approach. The company's focus on CD105—a protein identified as a key driver of resistance and disease relapse—differentiates it from other oncology therapeutics. With ENV-105 being evaluated in both Phase 1 and Phase 2 trials, the company is positioning itself in the competitive landscape of cancer drug development. The full press release is available at https://ibn.fm/PIrky, and the latest news and updates relating to KAPA can be found in the company's newsroom at https://ibn.fm/KAPA.
The announcement was disseminated through TinyGems, a specialized communications platform focused on innovative small-cap and mid-cap companies. TinyGems is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. Such widespread distribution ensures that important clinical findings reach a broad audience of investors, healthcare professionals, and the public. For more information on TinyGems, visit TinyGems. The company's disclaimer is available at https://www.TinyGems.com/Disclaimer.
